Akiko Itai

Institute of Medicinal Molecular Design — Japan

Biochemistry, Genetics and Molecular Biology · Life Sciences

44h-index6.3kcitations251works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

NF-κB Signaling Pathways(25), Chemical Synthesis and Analysis(20), Computational Drug Discovery Methods(19), Analytical Chemistry and Chromatography(19), Natural product bioactivities and synthesis(14)

Publications250 total

Design, Synthesis, and Anti-Inflammatory Evaluation of a Novel PPARδ Agonist with a 4-(1-Pyrrolidinyl)piperidine Structure
Journal of Medicinal Chemistry·2023· 8 citedOpen Access
Supplemental Figure Legend from IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment
2023Open Access
Data from IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment
2023Open Access
Supplemental Table 1 from IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment
2023Open Access
Supplemental Table 2 from IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment
2023Open Access
Supplemental Table 1 from IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment
2023Open Access
Supplemental Figure 1 from IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment
2023Open Access
Data from IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment
2023Open Access
Supplemental Table 2 from IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment
2023Open Access
Supplemental Figure Legend from IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment
2023Open Access
Supplemental Figure 1 from IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment
2023Open Access
Discovery and structure-activity relationship study of 2-piperazinyl-benzothiazole derivatives as potent and selective PPARδ agonists
Bioorganic & Medicinal Chemistry·2023· 3 citedOpen Access
Discovery and structure-based design of a new series of potent and selective PPARδ agonists utilizing a virtual screening method
Bioorganic & Medicinal Chemistry Letters·2022· 3 citedOpen Access
Attenuation of experimental autoimmune uveoretinitis in mice by IKKβ inhibitor IMD-0354
Biochemical and Biophysical Research Communications·2020· 5 cited
IKK<i>β</i> Inhibitor IMD-0354 Attenuates Radiation Damage in Whole-body X-Irradiated Mice
Oxidative Medicine and Cellular Longevity·2019· 6 citedOpen Access
A novel IkB kinase inhibitor attenuates ligature‐induced periodontal disease in mice
Journal of Periodontal Research·2018· 13 cited
Plasminogen activator inhibitor-1 is an independent prognostic factor of ovarian cancer and IMD-4482, a novel plasminogen activator inhibitor-1 inhibitor, inhibits ovarian cancer peritoneal dissemination
Oncotarget·2017· 39 citedOpen Access
Targeting IKKβ prevents inflammation-induced preterm delivery by inhibiting interleukin-6 production from amniotic cells
Placenta·2016
The Novel IκB Kinase β Inhibitor, IMD-0560, Has Potent Therapeutic Efficacy in Ovarian Cancer Xenograft Model Mice
International Journal of Gynecological Cancer·2016· 1 cited
Targeting Inhibitor of κB Kinase β Prevents Inflammation-Induced Preterm Delivery by Inhibiting IL-6 Production from Amniotic Cells
American Journal Of Pathology·2016· 13 citedOpen Access
page 1 of 13Next →

Frequent Co-authors

Yöichi Iitaka(11), Susumu Muto(11), Koichi Shudo(10), Nobuo Tomioka(8), Hiroyuki Kagechika(6), Yasuyuki Endo(6), Asako Kubo(4), Toru Iijima(3), Hiroshi Fukasawa(3), Yoshiharu Toriumi(3), Kazunori Odashima(3), Go Haraguchi(3), Mitsuaki Isobe(3), Yasuhiko Nishioka(3), Miho Mizutani(3), Yuichi Kato(3), Naoko H. Tomioka(3), Toshimasa Yamauchi(2), Junji Kamon(2), Ryozo Nagai(2)